CliffBio
small molecule

CISATRACURIUM BESYLATE

CISATRACURIUM BESYLATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameCISATRACURIUM BESYLATE
Active ingredientCISATRACURIUM BESYLATE
StrengthEQ 2MG BASE/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalFebruary 2015
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.